SynthesisBMC oral health2026
Efficacy of theracal as pulp capping material in permanent dentition: a systematic review and meta-analysis.
Synthesis in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVital pulp therapy (VPT) aims to preserve pulp vitality through minimally invasive approaches, including indirect pulp capping (IPC), direct pulp capping (DPC), and pulpotomy. TheraCal LC, a light-cured resin-modified calcium silicate material, is widely used as a pulp-capping agent due to its favorable handling characteristics and bioactive properties. However, its clinical and radiographic efficacy remains insufficiently documented.
objectiveThis systematic review and meta-analysis evaluated the effectiveness of TheraCal LC in IPC and DPC procedures and compared its performance with other pulp-capping materials, including mineral trioxide aggregate (MTA), calcium hydroxide, and Biodentine.
methodsA comprehensive search of PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials was conducted up to August 2025. Randomized controlled trials assessing TheraCal LC in IPC or DPC of permanent teeth were included. Study selection, data extraction, and risk of bias assessment (ROB-2) were performed independently by multiple reviewers. Meta-analyses were conducted using random-effects models, with subgroup analyses based on follow-up duration.
resultsFrom 606 records identified across four databases, 11 clinical studies published between 2015 and 2025 met the inclusion criteria. These studies compared TheraCal LC with calcium hydroxide, Biodentine, and MTA in IPC and DPC. TheraCal LC demonstrated comparable clinical success rates to other materials, with consistently low pain scores and satisfactory dentin bridge formation during follow-up periods of 6-36 months. Risk of bias assessment indicated that most studies presented some concerns, primarily related to randomization and selective reporting, although overall methodological quality was acceptable.
conclusionsTheraCal LC represents a viable alternative to MTA, calcium hydroxide, and Biodentine for direct and indirect pulp capping in permanent teeth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.